Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DMTK - DermTech, Inc.

Close
0.094
-0.012   -12.766%

Share volume: 3,662,379
Last Updated: Wed 26 Jun 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$0.11
-0.01
-11.32%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
12%
Profitability 7%
Dept financing 9%
Liquidity 75%
Performance 3%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.09
P/E Ratio 
0.00
DAY RANGE
$0.09 - $0.10
EPS 
-$2.66
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
35.262 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: John D. Dobak
Region: US
Website: dermtech.com
Employees: 260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

DermTech, Inc. develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners.

Recent news